|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we found that targeting βig-h3 in established lesions released the tissue tension and functionally reprogrammed F4/80 macrophages in the tumour microenvironment.
|
30415234 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We further confirmed that high expression level of TGFBI can promote proliferation, invasive progression, and epithelial-to-mesenchymal transition (EMT) of BCa cells in vitro, as well as promote tumor growth and EMT in vivo, while silencing of TGFBI inhibited these malignant phenotypes.
|
31440088 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, the xenograft animal study showed that TGFBI knockout suppressed tumor growth and metastasis in vivo.
|
31598162 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor signals regulate transforming growth factor-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells via Elk1.
|
31094056 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, after administration of TGF-β1 (increasing TGFBI level), the volume of tumor is obviously reduced in nude mice with injection of L02 cells stable expressing truncated HBsAg.
|
29609638 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transforming growth factor β-induced (TGFBI) protein is a secreted extracellular matrix protein with conflicting roles in cancer, acting as a tumour suppressor and a promoter, which appears to be tissue specific.
|
30260476 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line.
|
30156359 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that BIGH3 acts as a tumor suppressor in the retina.
|
28099942 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our findings demonstrate that TGFBIp is a lymphangiogenic factor contributing to tumor dissemination and represents a potential target to inhibit metastasis.
|
25772247 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant association was found between the presence of TGFBI expression with tumor category T3-4 (P<0.0001), Fuhrman grades III and IV (P<0.0001), tumor size>4cm (P<0.0001), presence of tumor necrosis (P<0.0001), nodal involvement (n = 0.009), metastasis (P = 0.012), SSIGN score≥5 (P<0.0001), cancer progression (P<0.0001), and cancer-specific death (P<0.0001).
|
25035170 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transforming growth factor β‑induced (TGFBI) has been implicated as a tumor suppressor, which enhances gemcitabine chemosensitivity in lung cancer cells.
|
26503734 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was found that the positive ratio of βig-h3 in the gastric cancer group was higher than that in the benign disease group, and the positive rate of immunohistochemistry was closely related to the relative factors of peritoneal metastasis such as tumor infiltration depth, serosal types, macroscopic peritoneal metastasis, CEA mRNA, results of pleural lavage cytology (PLC) examination, etc.
|
25864756 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
|
25284464 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BXPC3 tumor xenografts demonstrated reduced growth with DDR1 knockdown, and the same xenograft tumors exhibited an increase in TGFBI expression level.
|
25369402 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When 95 high-grade serous EOCs were grouped by genes based on ANOVA comparing ESR1/WT1 and POSTN/TGFBI samples, overall survival (OS) was significantly shorter for 43 patients with tumors expressing genes associated with POSTN/TGFBI compared to 52 patients with tumors expressing genes associated with ESR1/WT1 (median 30 versus 49 months, respectively; P = 0.022).
|
24368280 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.
|
24791868 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results support the theory that TGFBI acts as a potent endogenous anti-tumor and anti-angiogenic molecule by targeting αvβ3 integrin, and highlights the importance of physiological circulating TGFBI levels in inhibiting tumor growth.
|
23792174 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of the present study suggest that TGFBI-promoted metastasis of RCC cells depends on inactivation of the VHL tumor suppressor and that TGFBI could be a therapeutic target against RCC in the future.
|
22341602 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, ectopic expression of TGFBI was used to ascertain its role as a tumor suppressor and to determine the underlying mechanism of mesothelioma and breast cancer.
|
22695319 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is known that βig-h3 is involved in the invasive process of many types of tumors, but its mechanism in glioma cells has not been fully clarified.
|
22629380 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By contrast, the expanding control tumors showed intense TGFBI staining at the tumor edges, co-localizing with the fibrillar fibronectin/tenascin-C/periostin structures that characteristically surround melanoma cells at invasion fronts.
|
22326753 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TGFBI, a secreted protein that is induced by transforming growth factor-β in various human cell types, has been shown to be associated with tumorigenesis in various types of tumors.
|
21701776 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The observations that TGFBI knock-out animals showed increased spontaneous tumor incidence and chemically induced tumors highlight the suppressive nature of the gene.
|
21901626 |
2011 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
TGFBI methylation was observed in 23 out of 38 (60.5%) cases of ovarian cancer, in no normal ovarian tissues (0 of 38, P=0.001), and in 5 out of 18 (27.8%) borderline tumors (P=0.044).
|
20421128 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We then used the MTg-AMO approach to identify several tumor suppressors-TGFBI, APC and BCL2L11 as the target genes for oncogenic miR-21, miR-155 and miR-17-5p, respectively, and two cardiac ion channel genes HCN2 (encoding a subunit of cardiac pacemaker channel) and CACNA1C (encoding the alpha-subunit of cardiac L-type Ca(2+) channel) for the muscle-specific miR-1 and miR-133.
|
19136465 |
2009 |